ISIN:NL0015436031

EQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK

Retrieved on: 
Wednesday, April 10, 2024
GSK, Ageing, CureVac, CVAC, Antigen, Messenger, Candidate, Safety, Vaccine

The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate.

Key Points: 
  • The multivalent candidate was selected from a comprehensive Phase 1 part, which tested vaccine candidates with up to eight separate mRNA constructs per candidate.
  • Targeted optimizations to further improve immune responses against influenza B strains will be tested in an additional Phase 2 study.
  • “The Phase 2 interim data show that CureVac’s highly effective and flexible mRNA technology platform puts us on the right track to advance our joint seasonal influenza vaccine program,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.
  • For older adults, immune responses were compared to a high dose seasonal flu vaccine.

EQS-News: CureVac gibt vielversprechende Interim-Phase-2-Daten aus Entwicklungsprogramm für saisonalen Grippeimpfstoff in Zusammenarbeit mit GSK bekannt

Retrieved on: 
Wednesday, April 10, 2024
Mittelwert, Titer, Erwartung, Kandidat, Erkenntnis, Plattform, Dosis, NASDAQ, Unternehmen, Zusammenarbeit, GSK, Anzahl, Grippe, Der Kandidat (2008), WHO, Ergebnis, Curevac, Generation, Generation (Gesellschaft), Optimum, Immunantwort, Weg, Doktor, Chief, Officer, Sicherheit, Antigen, Impfstoff, Gebiet, MRNA, Partnerschaft, GSK (Pharmaunternehmen), Produkt, Bereich, Infektionskrankheit, Entwicklung

EQS-News: CureVac veröffentlicht positive Interim-Phase 2-Daten des COVID-19-Impfstoff-Entwicklungsprogramms in Zusammenarbeit mit GSK, die starke Validierung der firmeneigenen Technologie-Plattform belegen

Retrieved on: 
Friday, January 5, 2024
Curevac, Zusammenarbeit, GSK, Validierung, Kandidat, Dosis, NASDAQ, Unternehmen, Phase, COVID-19, Ergebnis, Generation, Immunantwort, Vergleich, Impfstoff, Doktor, Chief, Officer, Weg, Sicherheit, Peplomer, Der Kandidat (2008), Titer, Impfung, Entwicklung, BA.4

EQS-News: CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform

Retrieved on: 
Friday, January 5, 2024
Messenger, CVAC, Vaccine, Ageing, Vaccination, Omicron, GSK, COVID-19, Interim, CureVac, Safety

Both vaccine candidates are being developed in collaboration with GSK.

Key Points: 
  • Both vaccine candidates are being developed in collaboration with GSK.
  • Selected data can be reviewed in the presentation associated with this press release.
  • All three of the dose levels tested were below those used in mRNA-based COVID-19 vaccines licensed in the U.S. and EU.
  • “These positive Phase 2 data continue to strongly validate the competitiveness of our proprietary mRNA-technology platform and second-generation mRNA backbone in comparison to a licensed mRNA-based vaccine,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.

EQS-News: CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Retrieved on: 
Tuesday, December 26, 2023
BioNTech, CVAC, Federal court, Patent, Federal Patent Court (Germany), Messenger, COVID-19, CureVac, Bird, Vaccine, Justice, Sąd rejonowy, COVID-19 vaccine, EP 1, Intellectual property, LLP

CureVac will appeal before the German Federal Court of Justice.

Key Points: 
  • CureVac will appeal before the German Federal Court of Justice.
  • The ruling represents a first decision on validity in ongoing patent litigation between CureVac and BioNTech SE in Germany, which involves a total of eight CureVac intellectual property rights.
  • “We consider the patent court’s decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year.
  • The decision is only one of many that will be made regarding the use of CureVac’s intellectual property in the development of Comirnaty®.

EQS-News: CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

Retrieved on: 
Tuesday, December 26, 2023
Survival, Research and development, BioNTech, CureVac, Workforce, Operating cost, GSK, Epitope, Webcast, Safety, Business development, RNA, CVAC, Conference, Sąd rejonowy, Astrocytoma, Neoplasm, Pfizer–BioNTech COVID-19 vaccine, Development, Vaccine, Commercial, LNP, Phase II, Acquisition, Immortalised cell line, Animal, GMP, Interim, Palatine Higher Regional Court, Patent, SARS-CoV-2, Tumor microenvironment, Toxicity, Glioblastoma, Antigen, Therapy, Research, Messenger, Mouse, COVID-19, Infection, Clinical trial, District court, Cancer, Patient, CMO, CD8

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – November 14, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the third quarter and first nine months of 2023 and provided a business update.
  • Positive preliminary data reported in early 2023 in COVID-19 and flu provided strong validation of CureVac’s mRNA technology platform.
  • All jointly tested candidates are based on CureVac’s proprietary second-generation mRNA backbone, targeting improved intracellular mRNA translation for early and strong immune responses.
  • The first nine months of 2022 were positively impacted by €36.8 million related to the reversal of an outstanding CRO provision.

EQS-News: CureVac gibt Urteil des Bundespatentgerichts zur Patentgültigkeit in breitem Patentstreit mit BioNTech SE bekannt

Retrieved on: 
Friday, December 22, 2023
Urteil, Wirkung, Verfahren, Curevac, N.V., NASDAQ, Unternehmen, Basis, Bundespatentgericht, Nichtigkeitsklage, Biontech, SE, EP, B1, Patent, Bundesgerichtshof, Berufung, Entscheidung, Geistiges Eigentum, Verletzung, Gericht, Anfang, Bezug, Nutzung, Eigentum, Entwicklung, Pionier, Innovation, Gebiet, Beitrag, Doktor, Bedeutung, Verlauf, COVID-19-Pandemie, Rolle, Impfstoff, Anspruch, Anerkennung, Bird, LLP, MRNA, Partnerschaft, GSK (Pharmaunternehmen), GSK, Produkt, Bereich, Infektionskrankheit, Generation, Zusammenarbeit, Sitz (juristische Person), Mitarbeiter, Standort, Mark H. McCormack Medal

EQS-News: CureVac veröffentlicht Finanzergebnisse für das dritte Quartal sowie die ersten neun Monate 2023 und informiert über seine Geschäftsentwicklung

Retrieved on: 
Wednesday, December 13, 2023
Infektionskrankheit, Start, Gewinn- und Verlustrechnung, Glioblastom, Kosten, Datum, Rekrutierung, Partnerschaft, Generation, COVID-19, Bereich, Meilenstein, Zusammenarbeit, Produktion, Monat, Teilnehmer, Basis, Linie, Dosis, NASDAQ, Impfstoff, Grippe, Curevac, Million, Reihe, Phase, Vorkasse, Produkt, Entwicklung, Faktor, Forschungs- und Entwicklungskosten, Quartal, Abschluss, Kandidat, Ergebnis, Impfung, Gewinn, Anfang, Studie, Zeitmanagement, Zusammenhang, Unternehmen, Remco, GSK, CMO, MRNA, RNA, GSK (Pharmaunternehmen), Internet

EQS-News: CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK

Retrieved on: 
Tuesday, November 7, 2023
SARS-CoV-2, Safety, Antigen, Messenger, COVID-19, CureVac, Interim, CVAC, GSK, Vaccine

“Through the successful execution of Phase 1 and 2 studies, together with our partner GSK, we are on track to move our most advanced COVID-19 and seasonal flu programs forward into the later stages of clinical development,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.

Key Points: 
  • “Through the successful execution of Phase 1 and 2 studies, together with our partner GSK, we are on track to move our most advanced COVID-19 and seasonal flu programs forward into the later stages of clinical development,” said Dr. Myriam Mendila, Chief Development Officer of CureVac.
  • In the joint seasonal flu development program, the first participant was dosed in the Phase 2 part of the combined Phase 1/2 study, following selection of a promising vaccine candidate based on positive Phase 1 interim data announced September 12, 2023 .
  • It was selected from the Phase 1 part of the study that compared a comprehensive series of multivalent, modified mRNA seasonal flu vaccine candidates with up to eight separate mRNA constructs per candidate.
  • In Phase 2, the selected candidate will be tested in younger and older adults at different dose levels compared to age-appropriate licensed seasonal flu comparator vaccines.